NervGen Pharma Corp. announces that patient enrollment for its Phase 1B/2a CONNECT-SCI clinical trial targeting individuals with quadriplegia due to subacute spinal cord injury is nearing completion.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
With the achievement of this key milestone, the company will next proceed with data unblinding to assess the efficacy and safety of its candidate drug. This development marks a significant step forward in the clinical development of the drug in the field of neural repair.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
A recorder hidden in toilet paper exposes OpenAI's long-standing safety issues
MEnews•2026/11/04 02:57
AbbVie (ABBV.US) expands Oxford R&D facility in UK, betting on innovation in immunology, neuroscience, and oncology drugs
AbbVie announced on Wednesday that, as part of an investment plan exceeding 120 million pounds (approximately $161 million), the company has expanded its research and development facility in Oxford, United Kingdom.
智通财经•2026/11/04 02:51
BNB fell below $690
金色财经•2026/11/04 02:37
Crypto prices
More
Bitcoin
BTC
$76,238.77
-0.72%
Ethereum
ETH
$2,242.97
-0.22%
Tether USDt
USDT
$0.9986
+0.03%
BNB
BNB
$685.9
-1.16%
XRP
XRP
$1.26
+0.49%
USDC
USDC
$0.9998
+0.02%
Solana
SOL
$90.7
-1.40%
TRON
TRX
$0.3213
+0.10%
Hyperliquid
HYPE
$82.32
-0.50%
Zcash
ZEC
$1,174.52
+3.17%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now